Utilizing the Paradigm cancer diagnostic (PCDx) for molecular profiling helps guide selection of standard chemotherapies, targeted therapies or supports the implementation of clinical trials for cancer patients through JIT in five to fifteen business days. This patient-centric diagnostic approach is designed to rapidly and more effectively treat patients by bringing all of the actionable mutations, targeted therapies and clinical trial options to the treating physician.
Dr. Matthew Wiener, Chief Scientific Officer of Pharmatech, commented, “This level of rapid analysis, molecular detail and evidence-based treatment options for standard and investigational treatments will be an unprecedented weapon in our war on cancer.”
The comprehensive molecular testing will be performed by Paradigm at their commercial laboratory at the University of Michigan. The Paradigm PCDx test evaluates over 500 molecular abnormalities and delivers those results in one week to the treating physician. The test evaluates the known, clinically actionable mutations for solid tumor malignancies, and provides specific associations for potential FDA approved therapies and investigational treatments.
The success of the clinical trials matching portion of Paradigm’s tumor profiling service is accelerated and augmented by Pharmatech’s clinical trials on-demand system called Just-In-Time (JIT). The proven JIT enrollment model can identify a patient, fully register the physician as a site in the clinical trial of interest and enroll the individual patient in 10 business days or less. The JIT model is augmented by a cloud based research portal that lists all the available trials and automates many of the repetitive regulatory activities.
“In the time required for most patients to receive limited molecular testing, we can deliver a well matched clinical trial to the treating oncologist and help individual patients receive precision investigational treatments in their community,” added Dr. Wiener.
“Personalized medicine is available for oncology patients today. Paradigm is pleased to partner with Pharmatech to deliver the best in class molecular diagnostic profiling and patient driven clinical trial service to physicians and their patients in a collaboration that truly facilitates a near immediate translational patient care,” commented Dr. Robert Penny, Paradigm’s CEO.
Paradigm’s PCDx is unparalleled in its capability to deliver to physicians a high quality comprehensive integrated genomic landscape of the patient’s cancer and associated therapies. This includes next generation mRNA expression, DNA mutations, copy number variation, insertions, deletions, base substitutions and gene rearrangements. This robust analysis helps facilitate the most sophisticated tailoring available today of a specific treatment regimen or clinical trial based upon the underlying molecular pathways of the individual patient’s tumor.
About Pharmatech, Inc.
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in the spectrum of patient treatment options.
For more information about Pharmatech’s cancer molecular diagnostic study, Just-In-Time clinical research, or enrolling clinical trials using our TrialPlus+ research platform, please contact:
Paradigm is a non-profit corporation established to bring cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients. Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment. Paradigm’s cancer diagnostic test, PCDx, provides oncologists with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. Paradigm, headquartered in Ann Arbor, Michigan with research facilities in downtown Phoenix, Arizona, is a collaboration between the University of Michigan Health System and the International Genomics Consortium.
For more information about Paradigm’s cancer diagnostic test, PCDx, please contact:
Manager, Business Development